
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
This trial looked at liposomal doxorubicin for people with an advanced T cell lymphoma of the skin called mycosis fungoides.
Cutaneous T cell lymphomas (CTCL) are types of non Hodgkin lymphoma that affect the skin. Mycosis fungoides is the most common of these, although it is still rare.
Doctors can use a number of different ways to treat CTCL. They usually use a combination of chemotherapy drugs to treat advanced CTCL. But this can have severe side effects.
Doctors thought that liposomal doxorubicin (Caelyx, Myocet or Doxil) may work as well on its own and have fewer side effects.
The aims of this trial were to find out
The researchers found that liposomal doxorubicin might work well for people with advanced mycosis fungoides CTCL.
This study recruited 49 people. Everyone had liposomal doxorubicin.
After completing their treatment, 20 of the 49 people had responded. Of these 20 people, for
The main side effects were
The researchers concluded that liposomal doxorubicin looked promising as a treatment for mycosis fungoides CTCL. And it should be looked at in further clinical trials.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists () but may not have been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Sean Whittaker
European Organisation for Research and Treatment of Cancer (EORTC)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.